

Trabectedin OVA-301

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Trabectedin OVA-301

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies
 Therapeutic Indication: In combination with PLD for the treatment of patients with relapsed platinum-sensitive ovarian cancer
 Experimental Arm: Trabectedin + Pegylated liposomal doxorubicin
 Control Arm: Pegylated liposomal doxorubicin

